Welcome to Merz Therapeutics North America

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is a global healthcare leader dedicated to improving the lives of patients around the world. With our relentless research, development, and culture of innovation, we strive to serve unmet patient needs and realize better outcomes.

Our Merz Therapeutics North America business is comprised of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C.

News

FDA APPROVES FIRST PEDIATRIC INDICATION FOR XEOMIN® (incobotulinumtoxinA) FOR THE TREATMENT OF UPPER LIMB SPASTICITY, EXCLUDING SPASTICITY CAUSED BY CEREBRAL PALSY

Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the first pediatric indication for XEOMIN® (incobotulinumtoxinA), for the treatment of patients aged 2 years and older with upper limb spasticity, excluding spasticity caused by cerebral palsy.

Read More

Xeomin® (IncobotulinumtoxinA) Celebrates 10 Years of Meeting the Needs of Patients Suffering from Movement Disorders

Merz Therapeutics is commemorating today the 10th anniversary of the first therapeutic approval of XEOMIN by the U.S. Food and Drug Administration.

Read More

MERZ FORMS FULLY FOCUSED GLOBAL MEDICAL AESTHETICS BUSINESS: MERZ AESTHETICS

Merz, a global leader in the field of aesthetics and neurotoxins, today announced plans to reorganize into three independently operating businesses: medical aesthetics, therapeutics and consumer care.

Read More